+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peritoneal Cancer - Pipeline Insight, 2021

  • ID: 5306348
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Aravive Biologics
  • Celsion
  • Hoffman-La-Roche
  • ImmunoGen
  • K Group Beta
  • Lee’s pharmaceuticals
This “Peritoneal Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Peritoneal Cancer Understanding

Peritoneal Cancer: Overview

Peritoneal cancer is is a rare form of cancer affecting the peritoneum, the thin membrane surrounding your abdominal organs. The causes of peritoneal cancer are unknown. Primary peritoneal cancer is more common in women than in men. The symptoms of peritoneal cancer resemble those of ovarian cancer. Many of these symptoms are due to buildup of fluid (ascites) in the abdomen. Peritoneal cancer symptoms may include: nausea, loss of appetite, vomiting, abnormal vaginal bleeding, rectum bleeding, feeling of fullness after breath and shortness of breath. Physical exam, Ultrasound, medical history are some procedures followed up for the diagnosis of peritoneal cancer. The treatment usually depends upon the size, location and stage of cancer.

"Peritoneal Cancer - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal Cancer pipeline landscape is provided which includes the disease overview and Peritoneal Cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

Peritoneal Cancer Emerging Drugs Chapters

This segment of the Peritoneal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal Cancer Emerging Drugs

Mirvetuximab Soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with peritoneal cancer.

Entinostat: Syndax Pharmaceuticals

Entinostat, is a selective, oral, once-weekly, class I HDAC inhibitor that has been studied in multiple solid tumors in combination with hormone therapy and several approved PD-1/PD-L1 antagonists. The drug is in phase I/II stage for the treatment of peritoneal cancer.

Peritoneal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Peritoneal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peritoneal Cancer

There are approx. 15+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. phase III include, Immunogen.

Phases

This report covers around 15+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal Cancer drugs.

Peritoneal Cancer Report Insights
  • Peritoneal Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Peritoneal Cancer Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Peritoneal Cancer drugs?
  • How many Peritoneal Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritoneal Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peritoneal Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aravive Biologics
  • Celsion
  • Hoffman-La-Roche
  • ImmunoGen
  • K Group Beta
  • Lee’s pharmaceuticals
Introduction

Executive Summary

Peritoneal Cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Peritoneal Cancer - Analytical Perspective

In-depth Commercial Assessment
  • Peritoneal Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Peritoneal Cancer Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Mirvetuximab Soravtansine: ImmunoGen
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I/II)
  • Comparative Analysis
Entinostat: Syndax Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical Stage Products
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Peritoneal Cancer Key Companies

Peritoneal Cancer Key Products

Peritoneal Cancer- Unmet Needs

Peritoneal Cancer- Market Drivers and Barriers

Peritoneal Cancer- Future Perspectives and Conclusion

Peritoneal Cancer Analyst Views

Peritoneal Cancer Key Companies

Appendix

List of Tables
Table 1 Total Products for Peritoneal Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Peritoneal Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Celsion
  • Hoffman-La-Roche
  • ImmunoGen
  • Syndax Pharmaceuticals
  • Immuno vaccine technologies, Inc.
  • Regeneron Pharmaceuticals
  • Aravive Biologics
  • K Group Beta
  • Lee’s pharmaceuticals
  • Y-mAbs Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll